ABCB1 and breast carcinoma: Other biomarkers have also been hypothesized to influence outcomes, such as the anti-apoptotic marker bcl-2 [29] and expression of the MDR1/ABCB1 drug efflux pump, for which upregulation has been associated with resistance to T-DM1 and other therapeutics in breast cancer [30–32].